Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.

Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.

Always stay updated with the free CMN Newsletter.

Hunterian Medicine

Main focus: Gene editing for the treatment of genetic diseases

Company stage: Pre-clinical

Diseases (gene editing): Undisclosed

Genome editing tool: CRISPR-MAD7, other undisclosed

Funding stage: Private

Location: Cambridge, MA, USA


Partners: Inscripta

Hunterian Medicine aims to enable CRISPR delivery within the limited AAV packaging capacity that currently represents one of the major challenges within therapeutic genome editing. The company is exploring a range of diseases and orphan indications for licensing and/or development, although it has yet to disclose targets and indications for its lead therapeutic programme.


HashtagHunterian Medicine

Company: Hunterian Medicine
Jobs, banner ads, webinars, sponsored content...
Search CRISPR Medicine